'Bottle Of Lies' Exposes The Dark Side Of The Generic Drug Boom
Generic drugs are supposed to work just as well as their name-brand counterparts.
Once a patent lifts, generic drug companies find alternative ways to manufacture a drug that should work indistinguishably from the name-brand version. In a world of skyrocketing prescription drug prices, cheaper generics have acted as a crucial counterweight.
But in , available Monday, investigative journalist and author Katherine Eban exposes the dangerous, dark side of some generics. Her propulsive narrative investigation traces the history of the generic drug boom, revealing how intense demand for cheaper drugs opened a dangerous chasm between what regulations required of drug companies and how some of those companies actually behaved. She also documents how the FDA struggled to address those safety gaps, and the challenges that still remain.
You’re reading a preview, subscribe to read more.
Start your free 30 days